Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | KCNN4 | O15554 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71942 | 0.94 | CYP2C9 (0.59) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| Bromoethane SCHEMBL221234 | 0.90 | CYP2C9 (0.50) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| SCHEMBL28905903 | 0.88 | CYP2C9 (0.52) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| SCHEMBL3227012 | 0.88 | CYP2C9 (0.64) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| SCHEMBL4619076 | 0.83 | CYP2C9 (0.55) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| Bromomethane SCHEMBL3163413 | 0.83 | CYP2C9 (0.55) | CYP2C9CYP2D6HIF1ARAB9ANPC1 | |
| Bromomethane SCHEMBL3169377 | 0.81 | CYP2C9 (0.57) | CYP2C9CYP2D6HIF1ARAB9ANPC1 | |
| SCHEMBL6785893 | 0.81 | CYP2C9 (0.45) | CYP2C9CYP2D6HIF1AKCNN4RAB9A | |
| Benzylic Acid SCHEMBL4823051 | 0.80 | CYP2C9 (0.65) | CYP2C9CYP2D6HIF1AKCNN4MEN1 | |
| Bromomethane SCHEMBL222144 | 0.79 | CYP2C9 (0.60) | CYP2C9CYP2D6HIF1ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652138-B2 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-26 | — | — | US | claimed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-2326374-B1 | INHALER | BOEHRINGER INGELHEIM INT (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| US-10556069-B2 | Inhaler | LUPIN LIMITED (IN) | 2020-02-11 | — | — | US | disclosed |
| US-20060002863-A1 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6951888-B2 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-04 | — | — | US | disclosed |
| US-20050154555-A1 | Measuring device for rapid non-destructive measurement of the contents of capsules | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | CYP2C9 250/4885CYP2D6 73/4885HIF1A 786/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP2D6 1790/4885HIF1A 422/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | CYP2C9 198/4885CYP2D6 57/4885HIF1A 1049/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | CYP2C9 715/4885CYP2D6 722/4885HIF1A 689/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP2D6 1790/4885HIF1A 422/4885 |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | CYP2C9 368/4885CYP2D6 162/4885HIF1A 3172/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | CYP2C9 3152/4885CYP2D6 1602/4885HIF1A 3548/4885 |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | CHRM1, CHRM2, ADRB1 | CYP2C9 297/4885CYP2D6 157/4885HIF1A 1034/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | CYP2C9 453/4885CYP2D6 252/4885HIF1A 1246/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | CYP2C9 162/4885CYP2D6 147/4885HIF1A 3108/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | CYP2C9 3425/4885CYP2D6 1222/4885HIF1A 136/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP2D6 1790/4885HIF1A 422/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP2C9 1982/4885CYP2D6 1790/4885HIF1A 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.